A double-blind, placebo-controlled study of vigabatrin three g/day in patients with uncontrolled complex partial seizures

Neurology

Volumn 46, Issue 1, 1996, Pages 54-61

  French, J A ^a   Mosier, M ^b   Walker, S ^b   Sommerville, K ^b   Sussman, N ^b  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^b SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; CARBAMAZEPINE 10,11 OXIDE; PHENOBARBITAL; PHENYTOIN; PRIMIDONE; VALPROIC ACID; VIGABATRIN;

ADULT; ANTICONVULSANT THERAPY; ARTICLE; CLINICAL TRIAL; COMPLEX PARTIAL SEIZURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DROWSINESS; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG ELIMINATION; DRUG TOLERANCE; FEMALE; FOCAL EPILEPSY; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

EID: 0029997934     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.46.1.54     Document Type: Article

References (24)

1. Grant SM, Heel RC. Vigabatrin: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in epilepsy and disorders of motor control. Drugs 1991; 41:889-926.
2. Lippert B, Metcalf BW, Jung MJ, Casara P. 4-Amino-hex-5-enoic acid, a selective catalytic inhibitor of 4-aminobutyric-acid aminotransferase in mammalian brain. Eur J Biochem 1977;74:441-445.
3. Palfreyman MG, Bey P, Sjoerdsma A. Enzyme-activated/ mechanism based inhibitors. Essays Biochem 1987;23:28-81.
4. Meldrum BS. GABAergic mechanisms in the pathogenesis and treatment of epilepsy. Br J Clin Pharmacol 1989;28(suppl 1):3-11.
5. Schechter PJ, Hanke NFJ, Grove J. Biochemical and clinical effects of γ-vinyl GABA in patients with epilepsy. Neurology 1984;34:182-186.
6. Grove J, Schechter PJ, Tell G, et al. Increased gamma-aminobutyric acid (GABA), homocarnosine and β-alanine in cerebrospinal fluid of patients treated with γ-vinyl GABA (4-amino-bex-5-enoic acid). Life Sci 1981;28:2431-2439.
7. Rimmer EM, Richens A. Double-blind study of γ-vinyl GABA in patients with refractory epilepsy. Lancet 1984;1:189-190.
8. Gram L, Klosterskov P, Dam M. γ-Vinyl GABA: a double-blind placebo-controlled trial in partial epilepsy. Ann Neurol 1985; 17:262-266.
9. Loiseau P, Hardenberg J, Pestre M, et al. Double-blind, placebo-controlled study of vigabatrin (gamma-vinyl GABA) in drug-resistant epilepsy. Epilepsia 1986;27:115-120.
10. Tartara A, Manni R, Galimberti CA, et al. Vigabatrin in the treatment of epilepsy: a double-blind, placebo-controlled study. Epilepsia 1986;27:717-723.
11. Reynolds EH, Ring HA, Farr IN, Heller AJ, Elwes RDC. Open, double-blind and long-term study of vigabatrin in chronic epilepsy. Epilepsia 1991;32:530-538.
12. Duncan J. Medical factors affecting quality of life in patients with epilepsy. In: Chadwick D, ed. Quality of life and quality of care in epilepsy. Roundtable series 23. London: Royal Society of Medicine, 1990.
13. Sivenius MRJ, Ylinen A, Murros K, Matilainen R, Riekkinen P. Double-blind dose reduction study of vigabatrin in complex partial epilepsy. Epilepsia 1987;28:688-692.
14. Mumford JP, Dam M. Meta-analysis of European placebo-controlled studies of vigabatrin in drug resistant epilepsy. Br J Clin Pharmacol 1989;27:101-107.
15. The Italian Study Group on Vigabatrin. Single-blind, placebo-controlled multicenter trial of vigabatrin in the treatment of epilepsy. Ital J Neurol Sci 1992;13:741-747.
16. Tartara A, Manni R, Galimberti CA, et al. Six-year follow-up study on the efficacy and safety of vigabatrin in patients with epilepsy. Acta Neurol Scand 1992;86:247-251.
17. Browne TR, Mattson RH, Perry JK, et al. Vigabatrin for refractory complex partial seizures: multiclinic single-blind study with long-term follow-up. Neurology 1987;37:184-189.
18. Rimmer EM, Richens A. Interaction between vigabatrin and phenytoin. Br J Clin Pharmacol 1989;27:27S-33S.
19. Matsuo F, Faught E, Messenheimer JA, et al. Placebo-controlled study of the efficacy and safety of lamotrigine in patients with partial seizures. Neurology 1993;48:2284-2291.
20. The US Gabapentin Study Group No. 5. Gabapentin as add-on therapy in refractory partial epilepsy: a double-blind, placebo-controlled, parallel-group study. Neurology 1993;43:2292-2298.
21. Gibson JP, Yarrington JT, Loudy DE, et al. Chronic toxicity studies of vigabatrin, a GABA-transaminase inhibitor. Toxicol Pathol 1990;18:225-238.
22. Dodrill CB, Arnett JL, Sommerville KW, Sussman NM. Evaluation of the effects of vigabatrin on cognitive abilities and quality of life in epilepsy. Neurology 1993;43:2501-2507.
23. Gorz AM, Bigarella MM, Mader MG, et al. Vigabatrin and cognitive function. Epilepsia 1990;31:643.
24. McGuire AM, Duncan JS, Trimble MR. Effects of vigabatrin on cognitive function and mood when used as add-on therapy in patients with intractable epilepsy. Epilepsia 1992;33:128-134.